Valneva (NASDAQ:VALN) shares declined on Monday after the UK Medicines and Healthcare products Regulatory Agency (MHRA) revoked the marketing authorisation for the company’s Ixchiq chikungunya vaccine following a review of its safety and benefit-risk profile.
The French vaccine developer said the decision followed an assessment by the UK’s Commission on Human Medicines based on previously available safety information. The company emphasised that the regulatory action was not prompted by any newly identified safety concerns.
The withdrawal applies specifically to the UK and does not affect Ixchiq’s marketing authorisations in the European Union, Canada, Brazil or other markets where the vaccine has received approval.
Valneva introduced Ixchiq in the UK in mid-2025, targeting travellers potentially exposed to the chikungunya virus. However, demand remained limited, and the company had already suspended active distribution in the country several months before the regulatory decision.
According to Valneva, no Ixchiq doses currently remain on the UK market, meaning the company does not anticipate any expenses associated with a product recall.
Management also expects the withdrawal to have only a minimal effect on future sales revenue, reflecting the vaccine’s limited commercial presence in the UK.
Valneva Maintains Positive Assessment of Ixchiq Safety Profile
Despite the MHRA’s decision, Valneva reiterated its position that Ixchiq maintains a favourable benefit-risk profile when administered in accordance with its approved indication.
The company pointed to additional safety information gathered following the vaccine’s introduction in several markets, including a pilot vaccination programme in Brazil.
More than 61,000 people aged between 18 and 59 have received Ixchiq through the Brazilian initiative, with no new safety concerns identified, according to Valneva.
Globally, approximately 187,000 doses of the vaccine have been administered.
The company also highlighted recent regulatory assessments conducted by the European Medicines Agency (EMA) and Health Canada.
Both authorities maintained their respective marketing authorisations for Ixchiq following safety reviews, although product information was updated to reflect the findings.
These decisions allow the vaccine to remain available in those jurisdictions under the applicable regulatory conditions.
Company Will Not Appeal UK Regulatory Decision
Although Valneva disagrees with the conclusions reached by UK regulators, the company has decided against appealing the withdrawal of its marketing authorisation.
Management cited the limited financial and commercial significance of the UK market for Ixchiq, indicating that pursuing an appeal would not align with its current business priorities.
Instead, Valneva intends to concentrate on expanding access to the vaccine in countries where chikungunya is endemic and the risk of infection is greater.
The company considers these markets more important to its longer-term commercial strategy, particularly given the continuing spread of the virus across several regions.
The decision to redirect resources towards endemic territories also reflects the relatively low demand for the vaccine among UK travellers since its launch.
Chikungunya Vaccine Targets Mosquito-Borne Viral Disease
Chikungunya is a viral infection transmitted through the bites of infected mosquitoes. The disease commonly causes fever, severe joint pain, muscle discomfort and other symptoms that can significantly affect patients.
Since 2004, the virus has been identified in more than 110 countries across Asia, Africa, Europe and the Americas.
The geographical spread of chikungunya has increased the importance of preventive measures, particularly in regions where mosquito populations and environmental conditions support transmission.
Valneva’s Ixchiq vaccine forms part of the company’s strategy to address infectious diseases for which preventive options have historically been limited.
While the UK authorisation withdrawal represents a regulatory setback, Valneva expects its direct financial impact to be minimal and plans to continue developing the vaccine’s commercial presence in other approved markets.